ArticleHaematologica2023

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.

Shinya Rai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.